Mast Cell Activation Syndrome Review Highlights Diagnostic Gaps and Research Needs
Mast cell activation syndrome (MCAS) remains one of the most debated conditions in allergy and immunology, according to a recent review published in The Journal of Allergy and Clinical Immunology. A recent review evaluates the growing body of literature on MCAS and the challenges clinicians face when diagnosing patients with suspected mast cell–mediated disease.
The authors note that although awareness of MCAS has increased substantially among both patients and healthcare professionals, significant uncertainty remains regarding its biological basis, diagnostic criteria, and prevalence.
MCAS is generally characterized by episodic symptoms attributed to mast cell mediator release affecting multiple organ systems, including the skin, gastrointestinal tract, cardiovascular system, and respiratory tract. However, the review emphasizes that many reported symptoms are nonspecific and overlap with numerous other medical conditions.
Findings
According to the authors, the diagnosis should be based on three key elements: the presence of recurrent symptoms consistent with mast cell activation, objective evidence of mast cell mediator release, and clinical improvement with therapies targeting mast cell mediators. Despite these proposed criteria, the review highlights ongoing challenges in obtaining reliable laboratory confirmation because available biomarkers have important limitations.
The authors also discuss the heterogeneity of conditions currently grouped under the MCAS label. They note that some patients have clonal mast cell disorders, whereas others may present with secondary mast cell activation or symptoms without clear evidence of mast cell involvement. This variability has contributed to confusion in both clinical practice and research settings.
A central message of the review is the need for standardized diagnostic approaches, validated biomarkers, and prospective studies to better define the syndrome and distinguish it from other disorders with overlapping symptom profiles.
Clinical Implications
The review has important implications for allergists, immunologists, gastroenterologists, dermatologists, and primary care physicians who frequently encounter patients presenting with complex multisystem symptoms.
The growing recognition of MCAS has led to increased referrals and patient demand for evaluation. However, the authors caution against overdiagnosis in the absence of objective evidence of mast cell activation. Misclassification may expose patients to unnecessary testing, inappropriate treatments, and delays in identifying alternative diagnoses.
For clinicians, the review reinforces the importance of a structured diagnostic workup that includes careful symptom assessment, measurement of validated mast cell mediators when appropriate, and exclusion of competing conditions. Objective biochemical confirmation remains a critical component of diagnosis.
The authors further emphasize that future research should focus on establishing more sensitive and specific biomarkers, clarifying disease mechanisms, and developing evidence-based treatment strategies. Improved standardization could help ensure more accurate diagnosis, facilitate clinical trial enrollment, and ultimately improve patient outcomes.
Reference
Valent P, Akin C, Castells M, et al. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol. 2024. Available at: https://www.jacionline.org/article/S0091-6749(24)00569-4/fulltext. Accessed June 19, 2026.
